In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Pharmaceuticals

This article was originally published in The Gray Sheet

Executive Summary

ReFacto R2 kit for recombinant antihemophilic factor VIII delivery, cleared via biologics license application supplement Sept. 10, provides the first available needleless reconstitution process for powdered factor VIII and a pre-filled diluent component for hemophilia treatment, the firm says. Eliminating two of the three needles used in Wyeth's previous ReFacto delivery kit, which was not pre-filled, the revised version incorporates a syringe made by Vetter, a vial adapter manufactured by Medimop and Braun infusion components. Priced the same as the earlier version, the next generation kit adds convenience, takes less time to use and will facilitate competition with factor VIII firm Baxter, Wyeth notes. A fourth quarter launch is anticipated...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT020926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel